View the programme from the ESMO Immuno Oncology Congress 2017
- Combining immune checkpoint inhibitors with chemotherapy or radiotherapy and beyond
- Patient selection and predictive biomarkers
- Management of side effects
- Resistance to therapy
- Imaging and nuclear medicine and design of immuno-oncology trials
- What’s new in specific cancer types
- Technological developments
- Future approaches: Adoptive T cell therapy, personalised vaccines, cancer neoantigens, use of bacteria for immunotherapy
The ESMO Immuno Oncology Congress 2017 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 22 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME with a maximum of 8 ECMEC®s per day.
The Congress programme has been accredited with 25 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification also guarantees that a certified medical oncologist has continued to update her/his knowledge and continue to possess the necessary skills and standards for the practice of medical oncology. See here for further details.
The Congress webcasts will include all the session of the official programme, where Speaker permission is granted, and will be available on this website and OncologyPRO for ESMO members.